{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:24:00Z","timestamp":1791829440738,"version":"4.3.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Yunnan Zhu Xiaofan Expert Workstation","award":["202105AF150070"],"award-info":[{"award-number":["202105AF150070"]}]},{"name":"Yunnan Zhu Xiaofan Expert Workstation","award":["202105AF150070"],"award-info":[{"award-number":["202105AF150070"]}]},{"name":"Yunnan Zhu Xiaofan Expert Workstation","award":["202105AF150070"],"award-info":[{"award-number":["202105AF150070"]}]},{"name":"Yunnan Zhu Xiaofan Expert Workstation","award":["202105AF150070"],"award-info":[{"award-number":["202105AF150070"]}]},{"name":"Yunnan Zhu Xiaofan Expert Workstation","award":["202105AF150070"],"award-info":[{"award-number":["202105AF150070"]}]},{"name":"Yunnan Zhu Xiaofan Expert Workstation","award":["202105AF150070"],"award-info":[{"award-number":["202105AF150070"]}]},{"name":"Sichuan Science and Technology Program","award":["2022YFS0622, 2022YFS0622-B4"],"award-info":[{"award-number":["2022YFS0622, 2022YFS0622-B4"]}]},{"name":"Sichuan Science and Technology Program","award":["2022YFS0622, 2022YFS0622-B4"],"award-info":[{"award-number":["2022YFS0622, 2022YFS0622-B4"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>During the treatment of 89 pediatric patients with Acute Myeloid Leukemia (AML) at the Hematology Department of Kunming Medical University\u2019s Children\u2019s Hospital from 2020 to 2023, three patients were identified to co-express the NUP98-NSD1, FLT3-ITD, and WT1 gene mutations. The bone marrow of these three patients was screened for high-risk genetic mutations using NGS and qPCR at the time of diagnosis. The treatment was administered following the China Children\u2019s Leukemia Group (CCLG)-AML-2019 protocol. All three patients exhibited a fusion of the NUP98 exon 12 with the NSD1 exon 6 and co-expressed the FLT3-ITD and WT1 mutations; two of the patients displayed normal karyotypes, while one presented chromosomal abnormalities. During the induction phase of the CCLG-AML-2019 treatment protocol, the DAH (Daunorubicin, Cytarabine, and Homoharringtonine) and IAH (Idarubicin, Cytarabine, and Homoharringtonine) regimens, in conjunction with targeted drug therapy, did not achieve remission. Subsequently, the patients were shifted to the relapsed\/refractory chemotherapy regimen C\u2009+\u2009HAG (Cladribine, Homoharringtonine, Cytarabine, and G-CSF) for two cycles, which also failed to induce remission. One patient underwent Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-HSCT) and achieved complete molecular remission during a 12-month follow-up period. Regrettably, the other two patients, who did not receive transplantation, passed away. The therapeutic conclusion is that pediatric AML patients with the aforementioned co-expression do not respond to chemotherapy. Non-remission transplantation, supplemented with tailor-made pre- and post-transplant strategies, may enhance treatment outcomes.<\/jats:p>","DOI":"10.1186\/s12887-024-04954-1","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T08:01:38Z","timestamp":1722067298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of three pediatric AML co-expressing NUP98-NSD1, FLT3-ITD, and WT1"],"prefix":"10.1186","volume":"24","author":[{"given":"Li","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zugang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qulian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,27]]},"reference":[{"issue":"20","key":"4954_CR1","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1182\/blood.2020007093","volume":"136","author":"NL Michmerhuizen","year":"2020","unstructured":"Michmerhuizen NL, Klco JM, Mullighan CG. Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. Blood. 2020;136(20):2275\u201389. https:\/\/doi.org\/10.1182\/blood.2020007093.","journal-title":"B-lood"},{"issue":"4","key":"4954_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et al. Diagnosis and management of AM-L in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"B-lood"},{"issue":"13","key":"4954_CR3","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1182\/blood-2011-04-346643","volume":"118","author":"IH Hollink","year":"2011","unstructured":"Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, et al. NUP98\/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118(13):3645\u201356. https:\/\/doi.org\/10.1182\/blood-2011-04-346643.","journal-title":"Blood"},{"issue":"2","key":"4954_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00277-022-05047-8","volume":"102","author":"H Sun","year":"2023","unstructured":"Sun H, Yan H, Yan Z, et al. Acute myeloid leukemia patients with NUP98:: NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT[J]. Ann Hematol. 2023;102(2):473\u20135. https:\/\/doi.org\/10.1007\/s00277-022-05047-8.","journal-title":"Ann Hematol"},{"key":"4954_CR5","unstructured":"World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed Chicago (17th edition); 2016."},{"key":"4954_CR6","doi-asserted-by":"publisher","first-page":"719803","DOI":"10.3389\/fped.2021.719803","volume":"9","author":"X Mao","year":"2021","unstructured":"Mao X, Yin R, Sun G, et al. Effects of TPMT, NUDT15, and ITPA genetic variants on 6-mercaptopurine toxicity for pediatric patients with acute lymph-oblastic leukemia in Yunnan of China[J]. Front Pead. 2021;9:719803. https:\/\/doi.org\/10.3389\/fped.2021.719803.","journal-title":"Front Pead"},{"issue":"7","key":"4954_CR7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/ped.14480","volume":"63","author":"G Pu","year":"2021","unstructured":"Pu G, Wang Y, Duan S, et al. NUDT15 polymorphism in healthy children with Bai nationality in Yunnan of China[J]. Pediatr Int. 2021;63(7):790\u20136. https:\/\/doi.org\/10.1111\/ped.14480.","journal-title":"Pediatr Int"},{"key":"4954_CR8","unstructured":"ISCN. An international system for human cytogenomic nomenclature. Second Edition. Basel: Karger; 2016."},{"issue":"10","key":"4954_CR9","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jmoldx.2021.07.012","volume":"23","author":"JK Tung","year":"2021","unstructured":"Tung JK, Suarez CJ, Chiang T, et al. Accurate detection and quantification of FLT3 internal tandem duplications in clinical hybrid capture next generation sequencing data[J]. J Mol Diagn. 2021;23(10):1404\u201313. https:\/\/doi.org\/10.1016\/j.jmoldx.2021.07.012.","journal-title":"J Mol Diagn"},{"issue":"3","key":"4954_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/leu.2016.267","volume":"31","author":"S Struski","year":"2017","unstructured":"Struski S, Lagarde S, Bories P, et al. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis[J]. Leukemia. 2017;31(3):565\u201372. https:\/\/doi.org\/10.1038\/leu.2016.267.","journal-title":"Leukemia"},{"issue":"10","key":"4954_CR11","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.3390\/cancers12102766","volume":"12","author":"S Mohanty","year":"2020","unstructured":"Mohanty S, Jyotsana N, Sharma A, et al. Targeted inhibition of the NUP98-NSD1 fusion oncogene in acute myeloid leukemia[J]. Cancers. 2020;12(10):2766. https:\/\/doi.org\/10.3390\/cancers12102766.","journal-title":"Cancers"},{"key":"4954_CR12","doi-asserted-by":"publisher","unstructured":"Niktoreh N, Walter C, Zimmermann M et al. Mutated WT1, FLT3-ITD, and NU -P98-NSD1 fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia[J]. J Oncol. 2019;2019. https:\/\/doi.org\/10.1155\/2019\/1609128.","DOI":"10.1155\/2019\/1609128"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-024-04954-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-024-04954-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-024-04954-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T08:02:34Z","timestamp":1722067354000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-024-04954-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,27]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4954"],"URL":"https:\/\/doi.org\/10.1186\/s12887-024-04954-1","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,27]]},"assertion":[{"value":"30 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received approval from the Ethics Committee of Kunming Children\u2019s Hospital [Approval No: IIT2020019-EC-2].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Written informed consent was obtained from the parents or legal guardians of the patients for the publication of this case report and any accompanying images. The consent includes permission to publish the patients\u2019 clinical details and any accompanying images. All identifying information has been removed or anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from the parents or legal guardians of all participants involved in the study. For participants under the age of 16, consent to participate was obtained from their parents or legal guardians.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no conflict of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"483"}}